GENE ONLINE|News &
Opinion
Blog

Kidney Disease
Novartis Plans to Acquire Chinook Therapeutics in a Potential $3.5B Deal, Revolutionizing IgAN Treatment Landscape
2023-06-14
Rona Therapeutics, Keymed Biosciences Team Up To Develop siRNA Drugs For Kidney Disease
2023-05-25
In-Home Kidney Disease Management Company, Monogram, Raises $375 Million
2023-01-13
Vera Therapeutics Eyes Phase 3 For Kidney Disease Candidate Following Positive Data
2023-01-04
Everest’s Renal Drug Gets Placed On Fast Track For Approval In Taiwan And Korea
2022-11-28
Alnylam Posts Positive Phase 2 Results for its RNAi Nephropathy Drug
2022-08-30
Ocelot’s Rare Kidney Disease Candidate Receives Orphan Drug Designation Going Into Phase 2 Trials
2022-08-23
Everest, Calliditas Win First Approval for Rare Kidney Disease Drug in Europe
2022-07-18
Roche Receives Rights to Ionis’ Antisense Kidney Disease Drug for $55 Million
2022-07-12
GSK’s Benlysta Bags Approval for Lupus Nephritis Treatment in China
2022-02-14
AM-Pharma Partners with Kyowa Kirin in $289m Deal for Kidney Drug
2021-09-09
FDA Approves Cara & Vifor’s CKD-Associated Pruritus Injection
2021-08-26
Venglustat’s Phase 2/3 Trial Failure Pushes Sanofi to Drop Kidney Disease Program
2021-06-02
FDA Approves Second Lupus Nephritis Drug in Two Months
2021-01-25
Chinook Therapeutics Completes Merger with Aduro BioTech Inc.
2020-10-05
LATEST
Ginkgo Bioworks and Pfizer Forge $331 Million Collaboration for RNA-Based Drug Discovery
2023-09-29
Johnson & Johnson Partners with Singapore to Boost Life Sciences Innovation
2023-09-28
Vietnam and South Korea Strengthen Cooperation in Multiple Sectors
2023-09-27
PeptiDream and Genentech Collaborate on Novel Peptide-Radioisotope Drug Conjugates
2023-09-27
AcuraStem and Takeda Collaborate on Innovative ALS Treatment
2023-09-27
Seven AI/ML for Life Sciences Companies Identified as Innovators in New Clarivate Companies to Watch Report
2023-09-27
GeneOnline’s Weekly News Highlights: Sept 17-Sept 22
2023-09-26
EVENT
2023-10-04
BioFuture 2023
New York city,USA
Scroll to Top